LY 3143921

Drug Profile

LY 3143921

Alternative Names: LY-3143921; LY3143921 hydrate

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Cancer Research UK; Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Jun 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in United Kingdom (PO) (NCT03096054)
  • 01 Feb 2017 Preclinical trials in Solid tumours in United Kingdom (PO) (Cancer Research UK pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top